Recently, the Tianjin Municipal Science and Technology Bureau released the "Announcement of the Second Batch of Technology-based Small and Medium-sized Enterprises in Tianjin in 2024". Among them, Laviana Pharma (Tianjin) Co., Ltd. was selected for the second batch of technology-based small and medium-sized enterprises in Tianjin in 2024.
It is understood that technology-based small and medium-sized enterprises refer to a group of small and medium-sized enterprises engaged in the research, development, production, and services of high-tech products, playing an important role in enhancing technological innovation capabilities, supporting sustainable economic development, and expanding social employment. Relying on a certain number of scientific and technological personnel engaged in scientific and technological research and development activities, obtaining independent intellectual property rights and transforming them into high-tech products or services, thus realizing sustainable development of small and medium-sized enterprises.
Over the years, Laviana Pharma (Tianjin) Co., Ltd. has been committed to the research and development of routes for innovative drugs and their key intermediates, custom synthesis, synthesis process development and optimization, quality research and method validation. Projects are transferred to production bases through technology transfer. With a professional R&D team, advanced equipment, and cutting-edge technology, the company continues to increase R&D investment, actively optimize industrial structure, and has been honored with many awards such as high-tech enterprises and technologically advanced service enterprises. It also holds multiple invention patents, technological intellectual property rights, and core technologies.
This recognition as a "technology-based small and medium-sized enterprise" not only fully affirms the research and development innovation capabilities of Laviana Pharma , but also further enhances the company's confidence in innovation-driven development. Laviana Pharma will continue to improve its core competitiveness with higher quality services and a pioneering spirit of innovation in the future development process, continuously introducing innovative scientific and technological products with independent intellectual property rights.